TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23072079
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Pinaverium, 50 mg orally, 3 times a day for 4 weeks).
Study: 24503140
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg)
Study: 11115818
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of lipid
Study: 9695140
Drug: Naloxone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.0 mg/kg)
Study: 7981009
Drug: Nadolol 5
Normalized name: bendroflumethiazide-nadolol 5 mg-40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 5 mg (N5)
Study: 7981009
Drug: Nadolol 20
Normalized name: nadolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 20 mg (N20)
Study: 7981009
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg (N80)
Study: 29386337
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) as an add-on to standard PR programme
Study: 18410636
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid booster (TTB) immunization, administered to 52 participants (15 from PI-sparing, 37 from PI-containing) at median 25 weeks after HAART initiation.
Study: 18410636
Drug: No TTB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TTB immunization, administered to 23 participants (6 from PI-sparing, 17 from PI-containing).
Study: 12204508
Drug: felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine (5 mg)
Study: 12204508
Drug: metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (50 mg)
Study: 12204508
Drug: enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (10 mg)
Study: 12204508
Drug: clinically prescribed
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinically prescribed medications
Study: 11151867
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg once daily), amoxicillin (1 g b.i.d.), and clarithromycin (500 mg b.i.d.) (EAC)
Study: 11151867
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg once daily), clarithromycin (500 mg twice daily) (EC)
Study: 11151867
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg once daily) (E)
Study: 11151867
Drug: Emergent resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergent resistance after treatment with EAC
Study: 8807099
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion GM‐CSF (GM‐CSF (CI))
Study: 8807099
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion GM‐CSF followed by sequential G‐CSF (GM‐CSF/G‐CSF)
Study: 8807099
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control patients receiving GM‐CSF as a 2‐h intravenous infusion (GM‐CSF (2‐h))
Study: 8807099
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion GM‐CSF (GM‐CSF (CI)) and GM‐CSF/G‐CSF
Study: 1581405
Drug: rhGM-CSF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF at a daily dose of 108 micrograms (group I)
Study: 1581405
Drug: rhGM-CSF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF at a daily dose of 216 micrograms (group II)
Study: 1581405
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of treatment
Study: 18034989
Drug: Amlodipine (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5‐10 mg)
Study: 31152476
Drug: everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI)
Study: 27645834
Drug: CBT-I (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-I (Cognitive Behavior Therapy for Insomnia)
Study: 26882041
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering therapy in patients with preserved LVEF (>55%)
Study: 26882041
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering therapy in patients with intermediate LVEF (45-55%)
Study: 26882041
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering therapy in patients with reduced LVEF (<45%)
Study: 25424952
Drug: Co-administered qHPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered qHPV and HAV/HBV vaccine
Study: 25424952
Drug: Separated doses
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separated doses of qHPV and HAV/HBV vaccine
Study: 25424952
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups post-second dose of qHPV and HAV/HBV
Study: 20080850
Drug: T(3) therapy
Normalized name: levothyroxine sodium 0.3 MG [Levo-T]
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(3) therapy (0.8 microg . kg(‐1) bolus; infusion 0.113 microg . kg(‐1) . h(‐1))
Study: 20080850
Drug: T(3) therapy
Normalized name: levothyroxine sodium 0.3 MG [Levo-T]
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(3) therapy
Study: 15290000
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg QD
Study: 15290000
Drug: Desipramine 50
Normalized name: desipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 50 mg BID
Study: 11710819
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg plus dexamethasone 10 mg
Study: 11710819
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg plus dexamethasone 10 mg
Study: 9164214
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial chemotherapy (HAI)
Study: 7967418
Drug: NHL-BFM 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHL-BFM 90 therapy
Study: 31959224
Drug: Tailored cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored cognitive behavioural therapy (CBT) intervention
Study: 31231865
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin (ATV) daily for a median of 27 days
Study: 23122836
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid (IL) infusion
Study: 11711768
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299V (LP299V) in liquid suspension
Study: 9204357
Drug: iopentol (Imagopaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol (Imagopaque 300 mg I/ml)
Study: 9204357
Drug: amidotrizoate (Peritrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: amidotrizoate (Peritrast 300 mg I/ml)
Study: 7953013
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral haloperidol
Study: 7953013
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oral haloperidol
Study: 7953013
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of oral haloperidol
Study: 7953013
Drug: Adjunctive lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive lorazepam (for non-responders)
Study: 3673203
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 3 micrograms given at 0, 1 and 6 months
Study: 3673203
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 3 micrograms given at 0, 1 and 2 months
Study: 23664712
Drug: Antidepressant pharmacotherapy
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant pharmacotherapy (three different regimens) for 12 weeks
Study: 21615671
Drug: muraglitazar (MURA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: muraglitazar (MURA), 5 mg/day
Study: 19560327
Drug: D-camphor-crataegus berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-camphor-crataegus berry extract combination (Korodin)
Study: 16469981
Drug: High-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.4 mg aglycone isoflavones/d)
Study: 16469981
Drug: Low-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg aglycone isoflavones/d)
Study: 11693319
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy with standardized 3-month omeprazole treatment
Study: 11693319
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standardized 3-month omeprazole treatment
Study: 3108171
Drug: Ritanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (20 mg daily)
Study: 3108171
Drug: Lorazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (5 mg daily)
Study: 30137281
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1-5 with concurrent radiotherapy 40 Gy, 2 Gy/fraction, 5 days a week)
Study: 30137281
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1-5)
Study: 26144968
Drug: Citalopram (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (serotonin reuptake inhibitor)
Study: 28116581
Drug: Atomoxetine (noradrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (noradrenaline reuptake inhibitor)
Study: 25945865
Drug: Carvedilol treatment
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol treatment (group A, n = 16)
Study: 25945865
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group B, n = 20)
Study: 23637276
Drug: Topical shellac
Normalized name: Shellac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical shellac
Study: 23637276
Drug: 10% povidone-iodine
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone-iodine (PVP-I) solution
Study: 21525157
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal testosterone replacement therapy
Study: 21525157
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Risedronate + Testosterone)
Study: 18972301
Drug: Pressurized metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered-dose inhaler
Study: 16432268
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablet (ODT) administered sublingually
Study: 16432268
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablet (ODT) administered normally
Study: 16432268
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral tablet (SOT)
Study: 8601566
Drug: MAB +
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB + MTX (methotrexate, 50 mg/m2/week)
Study: 8601566
Drug: MAB (orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB (orchiectomy followed by flutamide therapy)
Study: 6430328
Drug: Inhaled lactose-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lactose-free sodium cromoglycate powder (C)
Study: 31300595
Drug: Dexmedetomidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (100 µg)
Study: 24046070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IDH1 with CEA, CA125, and Cyfra21‐1
Study: 19584895
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (6 g ALA from 30 g flaxseed oil)
Study: 19584895
Drug: Ground flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground flaxseed (6 g ALA from 30 g ground flaxseed)
Study: 15029102
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg x 2/die)
Study: 15029102
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg/die)
Study: 1770553
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg/d)
Study: 29168028
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of steroids (prednisolone intravenously followed by methylprednisolone orally)
Study: 29168028
Drug: Intratympanic administration
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic administration of methylprednisolone
Study: 29168028
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of systemic and intratympanic steroids
Study: 24485548
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MMRV
Study: 24485548
Drug: MMR at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group)
Study: 24485548
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MMR (control group)
Study: 18600386
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Study: 18600386
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Study: 18600386
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, bismuth subcitrate, doxycycline, metronidazole)
Study: 18600386
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after quadruple therapy
Study: 16077384
Drug: Ginsenosides compound
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenosides compound (1.35 mg/kg intravenously before and throughout cardiopulmonary bypass)
Study: 11836266
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/d plus KCl placebo)
Study: 11836266
Drug: Hydrochlorothiazide (HCTZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl/d)
Study: 2901566
Drug: Ditiocarb sodium
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ditiocarb sodium ('Imuthiol') 10 mg/kg body weight given orally once a week
Study: 31738283
Drug: Dextrose prolotherapy
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose prolotherapy (5 ml of 30% dextrose, 4 ml of saline, and 1 ml of 2% lidocaine mixture)
Study: 31738283
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (9 ml of saline and 1 ml of 2% lidocaine mixture)
Study: 26946985
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/d
Study: 26946985
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (erlotinib alone 150 mg/d)
Study: 22538152
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm needle with 20 U insulin diluent
Study: 22538152
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm needle with 20 U insulin diluent
Study: 22538152
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm needle with 60 U insulin diluent
Study: 22538152
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm needle with 60 U insulin diluent
Study: 12881395
Drug: Oxaliplatin (OXA)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (OXA) 130 mg/m² over 2 hours
Study: 12881395
Drug: Oxaliplatin combined
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin combined with 5-fluorouracil (OXFU) 1000 mg/m²/day, continuous intravenous infusion, days 1-4
Study: 8663944
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (100 micrograms/d in each nostril)
Study: 8663944
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray (100 micrograms in each nostril every 12 hours)
Study: 1451923
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day astemizole for 3 days
Study: 1451923
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day loratadine for 3 days
Study: 1451923
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day terfenadine forte for 3 days
Study: 26583940
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 30% sucrose (group I, n=45)
Study: 24412523
Drug: Trimetazidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (35 mg orally twice a day)
Study: 18045264
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PCV)
Study: 15644067
Drug: Levodopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (125 mg)
Study: 15644067
Drug: Levodopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (125 mg) + Selegiline (5 mg)
Study: 10540928
Drug: Diazepam (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.7 mg/kg body weight)
Study: 10540928
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg/kg body weight)
Study: 7002707
Drug: Autologous intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous intestinal contents infusion
Study: 7002707
Drug: Artificial bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial bile acid solution infusion
Study: 30489441
Drug: Self-care breath
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care breath training program (30-min training followed by 15 min twice daily for 6 weeks)
Study: 16676077
Drug: Antithrombin (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (30,000 IU) over four days without concomitant heparin
Study: 16676077
Drug: Antithrombin (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (30,000 IU) over four days with concomitant heparin
Study: 16676077
Drug: Antithrombin (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (30,000 IU) without concomitant heparin
Study: 16676077
Drug: Antithrombin plus
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin plus concomitant heparin
Study: 16676077
Drug: Antithrombin with
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin with or without concomitant heparin
Study: 11373409
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of vasopressin at 0.04 units/min for 16 hrs
Study: 8481249
Drug: Glycopyrrolate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.2 mg intravenously)
Study: 10852273
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml saline solution)
Study: 3325934
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg enoxacin orally
Study: 3325934
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg enoxacin orally
Study: 3325934
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ciprofloxacin orally
Study: 3325934
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ciprofloxacin orally
Study: 3325934
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin orally
Study: 3325934
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g daily for seven days
Study: 20547904
Drug: 9 additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 additional months of oral valganciclovir (n = 70)